Qualification of a high-throughput luminescence-based Serum Bactericidal Activity assay to assess the functionality of human sera against five Shigella serotypes
Vaccine·
- DOI
- 10.1016/j.vaccine.2026.128965
- PMID
- 42501717
- PMCID
- —
- OpenAlex
- W7171307302
- Study type
- Journal article
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The study provides an assay method for evaluating functional antibody responses during development of Shigella vaccines. The abstract places this work in the context of shigellosis burden and antimicrobial-resistance concerns, but it does not report clinical effectiveness, disease reduction, or population-level outcomes.
Structured evidence summary
Research question
The study evaluated whether a luminescence-based Serum Bactericidal Activity assay could be qualified to measure serotype-specific functional antibody activity against five Shigella serotypes and support testing of multicomponent vaccine candidates.
Study design
This was a laboratory assay-qualification study conducted after transferring the method to a Clinical Research Organization. The qualification used pooled human serum samples and assessed repeatability, intermediate precision, linearity, and serotype-specific activity.
Population and setting
The assay was evaluated with pooled human serum samples against S. flexneri 2a, 1b, 3a, 6, and S. sonnei. The work involved a Clinical Research Organization and addressed use across different laboratories.
Main findings
The abstract reports that repeatability, intermediate precision, and linearity were confirmed, and that the assay detected serotype-specific Shigella antibody activity. It also states that the method could be performed by different laboratories and was considered suitable for testing multicomponent vaccine candidates.
Public-health relevance
The study provides an assay method for evaluating functional antibody responses during development of Shigella vaccines. The abstract places this work in the context of shigellosis burden and antimicrobial-resistance concerns, but it does not report clinical effectiveness, disease reduction, or population-level outcomes.
Important limitations
The evaluation used pooled serum samples and laboratory assay performance measures, so the abstract does not establish clinical protection or define a correlate of protection. This summary is limited to the supplied single-article abstract and metadata; the original paper is required for decision-grade interpretation.
GIDS interpretation
The article is discoverable in a shigellosis and vaccination context, with antimicrobial resistance also identified as a topic. It concerns laboratory support for vaccine evaluation and does not provide evidence about a live surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 8 auditable classifier relationships to diseases, places, topics, and study design.